On March 14, 2022 INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient’s immune system to fight disease, reported that RJ Tesi, MD., President and CEO has been invited to participate in the 32nd Annual Oppenheimer Healthcare Conference and the 2022 Maxim Group Virtual Growth Conference (Press release, INmune Bio, MAR 14, 2022, View Source [SID1234610171]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr Tesi will present a corporate overview at the 32nd Annual Oppenheimer Healthcare Conference, which is being held virtually on March 15 – 17, 2022.
Event Details
Date: Wednesday, March 16, 2022
Time: 11:20am ET
To set up 1X1 meetings with management, please contact your Oppenheimer representative.
Dr. Tesi will participate in a fireside chat with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group during the 2022 Maxim Group Virtual Growth Conference, which is being held virtually on March 28– 30, 2022.
Event Details
Date: Wednesday, March 30, 2022
Time: 11:00am ET
Register: https://m-vest.com/events/2022-virtual-growth-conference.